Table 2.

ORs for the association between obesity and risk of overall, low-grade, and high-grade prostate cancer in the REDUCE study

Overall cancerbLow-grade cancerb Gleason (≤6)High-grade cancerb Gleason (≥7)
CasesORa (95% CI)PCasesORa (95% CI)PCasesORa (95% CI)P
All men (N = 6,427)
 Crude analysis1,448 (23%)0.84 (0.72–0.98)0.0221,008 (16%)0.74 (0.62–0.89)0.001440 (7%)1.08 (0.86–1.37)0.50
 Adjusted analysisa0.92 (0.79–1.07)0.280.79 (0.65–0.94)0.011.28 (1.01–1.63)0.04
Placebo arm (N = 3,270)
 Crude analysis823 (25%)0.84 (0.69–1.03)0.10594 (18%)0.79 (0.62–0.99)0.04229 (7%)0.99 (0.71–1.39)0.98
 Adjusted analysisa0.92 (0.75–1.13)0.450.84 (0.66–1.06)0.151.18 (0.84–1.66)0.35
Dutasteride arm (N = 3,157)
 Crude analysis635 (20%)0.83 (0.66–1.04)0.11414 (13%)0.67 (0.50–0.89)0.006221 (7%)1.18 (0.85–1.65)0.32
 Adjusted analysisa0.91 (0.73–1.15)0.440.71 (0.53–0.95)0.021.41 (1.00–1.98)0.05
  • aAdjusted for age, race, PSA, DRE findings, TRUS volume, and study treatment arm.

  • bReferents were nonobese men (BMI <30 kg/m2) and no cancer.